Mavicon 100mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent effective against a variety of fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to fungal cell death. Mavicon is indicated for the treatment of systemic and superficial mycoses, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. It is particularly useful in patients who are intolerant or unresponsive to other antifungal therapies. The recommended dosage varies depending on the type and severity of infection, and treatment duration should be guided by clinical response and mycological findings. Mavicon 100mg Capsule should be taken with food to enhance absorption and bioavailability. Caution is advised in patients with hepatic impairment or congestive heart failure, and liver function tests should be monitored periodically during therapy. Potential adverse effects include gastrointestinal disturbances, headache, rash, and elevated liver enzymes. Mavicon may interact with several drugs metabolized by the cytochrome P450 system, necessitating careful review of concomitant medications. This formulation provides a convenient oral antifungal option for effective management of fungal infections under medical supervision.